In this study, STC2 was expressed in 71.7% of the 60 CRC cases (53.3% low grade positive +, and 18.3% high-grade positive ++) and 28.3% of the studied cases were STC2 negative. This evidence concerns the gene STC2 and colorectal carcinoma.